Dong-A Socio Group's Dong-A ST, ST Farm, and STzen Bio participated in Bio USA...joint booth operati...

Dong-A Socio Group Dong-A ST, ST Farm, and STzen Bio will participate in the 2025 Bio International Convention (BIO USA) held in Boston from the 16th to the 19th (local time) and run a joint booth.

Bio USA is the world's largest pharmaceutical and bio exhibition organized by the American Biotechnology Innovation Organization (BIO), and more than 20,000 pharmaceutical and bio industry officials from more than 70 countries around the world attend every year. Officials introduce R&D performance and pipelines and hold various business meetings to attract investment, export and introduce technology, and strengthen global partnerships.

At this exhibition, Dong-A ST, ST Farm, and STzen Bio plan to focus on promoting their unique technology and strategies to enter the global market. Dong-A ST President Park Jae-hong, President of R&D, ST Farm Sungmuje, and President Choi Kyung-eun of STzen Bio will hold business meetings and promotional activities directly at the on-site booth.

DongA ST introduces 14 pipelines in the clinical stage and 24 pipelines in the early and preclinical stages, including anticancer drugs, immune and inflammatory diseases, neurological diseases, and endocrine diseases. It also presents research results and development strategies in the field of new modality such as exosome-based drug delivery, mRNA-LNP-based technology, and AAV-mediated gene therapy. Its subsidiary, Aptis, is also heading to Boston for a business meeting. Aptis will introduce the technical differentiation and scalability of the ADC linker platform 'AppClick' and the current status of gastric and pancreatic cancer treatments 'AT-211(DA-3501)' targeting Claudin18.2.

STPharm will introduce high-quality synthesis technology and precision analysis capabilities of single guide RNA (sgRNA), a key component of CRISPR/Cas-based gene editing technology, an enzyme-based hybrid approach, the first Allosteric HIV-1 Integrase Inhibitor (ALLINI) candidate STP0404 to treat HIV with a new mechanism, and STP1002, which is being developed as a treatment for advanced solid cancer including colorectal cancer.

Based on FDA cGMP due diligence passing and EMA GMP certification, STzenbio promotes raw materials drug and PFS CMO services with proven quality systems and production capabilities from global regulators.

An official from Dong-A Socio Group said, `We will inform the world of the differentiated technology and competitiveness of Dong-A ST, ST Farm, and STzen Bio through Bio USA,' adding, `We will make efforts to lead to substantial business results such as technology exports, investment attraction, and global partnership expansion.'

compact@

Komentar

Postingan populer dari blog ini

Naomi Wins Women's WWE Money In The Bank 2025 Ladder Match

Michigan to Mexico City present tight NASCAR travel logistics

'Be very careful': Republican Senators get stern warning from one of their own